Journey Medical (DERM) director receives 10,000 RSU equity award, now holds 118,618 shares

Rhea-AI Filing Summary

Toledano Miranda Jayne reported acquisition or exercise transactions in this Form 4 filing.

Journey Medical Corp director Miranda Jayne Toledano received an equity award of 10,000 shares of common stock in the form of restricted stock units. The grant was made on June 25, 2026 under the company’s 2015 Stock Plan, as amended.

The 10,000 restricted stock units are scheduled to vest in full on June 25, 2027, increasing her time-based incentive to remain aligned with shareholders. After this grant, Toledano’s direct holdings, including other restricted stock units that vest over various periods, total 118,618 shares of Journey Medical common stock.

Insights

Equity compensation analyst

Routine RSU grant increases director’s equity stake without cash buying.

Director Miranda Jayne Toledano received 10,000 restricted stock units on June 25, 2026 at a stated price of $0.00 per share. This indicates an equity compensation award rather than an open-market purchase.

The award vests in a single tranche of 10,000 shares on June 25, 2027, creating a one-year retention and performance alignment period. Following the grant, her direct holdings, including other time-vesting RSUs, total 118,618 shares, suggesting this is a modest, routine refresh rather than a transformational change.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Toledano Miranda Jayne

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $0.0001 par value	10,000	$0.00	--

Holdings After Transaction: Common Stock, $0.0001 par value — 118,618 shares (Direct, null)

Footnotes (1)

1. On June 25, 2026, the reporting person was granted 10,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 10,000 shares on June 25, 2027. Includes restricted stock units, which vest over various time periods.

Key Figures

RSU grant size: 10,000 shares Grant price: $0.00 per share Post-grant holdings: 118,618 shares +2 more

5 metrics

RSU grant size 10,000 shares Restricted stock units granted on June 25, 2026

Grant price $0.00 per share Equity compensation award, not open-market purchase

Post-grant holdings 118,618 shares Total direct holdings after transaction, including RSUs

Vesting amount 10,000 shares RSUs vest on June 25, 2027

Transaction code A (Grant, award, or other acquisition) Non-derivative acquisition classified as equity grant

Key Terms

restricted stock units, 2015 Stock Plan, vest, Grant, award, or other acquisition

4 terms

restricted stock units financial

"the reporting person was granted 10,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2015 Stock Plan financial

"granted 10,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended"

vest financial

"which will vest in accordance with the following schedule: 10,000 shares on June 25, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Grant, award, or other acquisition regulatory

"transaction code description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:06 PM Accepted by SEC EDGAR 06/29/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Toledano Miranda Jayne

(Last) (First) (Middle)

C/O JOURNEY MEDICAL CORPORATION

9237 E VIA DE VENTURA BLVD., SUITE 105

(Street)

SCOTTSDALE ARIZONA 85258

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Journey Medical Corp [ DERM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.0001 par value	06/25/2026		A		10,000(1)	A	$0	118,618(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On June 25, 2026, the reporting person was granted 10,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 10,000 shares on June 25, 2027.

2. Includes restricted stock units, which vest over various time periods.

	/s/ Ramsey Alloush, attorney-in-fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Journey Medical Corp (DERM) disclose in this Form 4 for Miranda Jayne Toledano?

Journey Medical Corp reported that director Miranda Jayne Toledano received 10,000 restricted stock units on June 25, 2026. These equity awards increase her total direct holdings to 118,618 shares of common stock, including other RSUs that vest over time.

How many Journey Medical (DERM) shares did Miranda Jayne Toledano acquire in this transaction?

She acquired 10,000 shares in the form of restricted stock units. The grant was recorded at a price of $0.00 per share, reflecting an equity compensation award rather than a cash purchase in the open market.

When do the newly granted Journey Medical (DERM) restricted stock units vest?

The 10,000 restricted stock units granted to Miranda Jayne Toledano vest in full on June 25, 2027. This single vesting date creates a one-year period during which continued service and alignment with shareholder interests are encouraged.

What is Miranda Jayne Toledano’s total Journey Medical (DERM) share ownership after this Form 4?

After this grant, Toledano directly holds 118,618 shares of Journey Medical common stock. This total includes restricted stock units that vest over various time periods, as noted in the filing’s footnotes.

Is the Journey Medical (DERM) Form 4 transaction an open-market buy or an equity grant?

The transaction is an equity grant, not an open-market buy. The Form 4 identifies the code as a grant or award acquisition, and the reported price of $0.00 per share confirms it is compensation under the company’s stock plan.

Under which plan were the Journey Medical (DERM) restricted stock units granted to Miranda Jayne Toledano?

The 10,000 restricted stock units were granted pursuant to Journey Medical’s 2015 Stock Plan, as amended. This plan governs the terms, vesting schedule, and other conditions of equity awards made to eligible participants.